Precipio, Inc. (PRPO)
| Previous Close | 5.81 |
| Open | 5.71 |
| Bid | 4.91 x 100 |
| Ask | 6.81 x 100 |
| Day's Range | 5.71 - 6.19 |
| 52 Week Range | 4.75 - 14.80 |
| Volume | |
| Avg. Volume | 3,593 |
| Market Cap | 8.7M |
| Beta (5Y Monthly) | 1.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.51 |
| Earnings Date | May 15, 2024 - May 20, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.00 |
GlobeNewswirePrecipio Secures a short-term $500K Credit Facility
Loan will supplement any temporary cashflow deficit related to cash collections delay due to Change Healthcare cybersecurity attackNEW HAVEN, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces it has secured a short-term loan facility of $500K to deal with any delays in cash collections due to the recent cybersecurity attack on Change Healthcare, a healthcare billing company used by a significant part of the healthcare market. Ma
- GlobeNewswire
Precipio Announces Year end 2023 Shareholder Update Call
Conference Call to be held on April 1st, 2024 at 5:00 PM EDTNEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its year end 2023 corporate update call on April 1st, 2024 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc.
- GlobeNewswire
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
Company continues to make strides towards breakevenNEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that for the full year of 2023, its unaudited revenues have grown from $9.4M in 2022 to $15.2M in 2023, an increase of 60% year over year. Both pathology and products divisions have demonstrated substantial growth from 2023, with the pathology services division increasing revenue by 52%, and the products division incr
